Background: Currently, there is an urgent need to find ways of identifying primary membranous nephropathy (PMN) patients who are likely to benefit from calcineurin inhibitors (CNI) or who are resistant to them. In this study, we employed nano-HPLC-MS/MS analysis to identify serum biomarkers that predict the clinical response to CNI therapy in PMN patients. Methods: The endpoint was complete remission (CR) after CNI treatment. PMN patients were grouped into no-remission (NR) or CR groups to screen predictive candidates using the nano-HPLC-MS/MS analysis. Results: Compared with NR patients, 3 upregulated proteins and 5 downregulated proteins were found to present a twofold change in CR patients’ serum. Serum amyloid A1 protein (SAA1) was further validated by ELISA; it was decreased in patients in the NR group compared with patients in the CR group, but SAA1 in patients in these groups was lower than in healthy controls and minimal change disease patients. The area under the receiver operating characteristic (ROC) curve of SAA1 was used to distinguish PMN NR patients from those in remission and was 0.901, with a sensitivity of 78.3% and specificity of 86.8%, similar to that of the phospholipase A2 receptor (PLA2R) antibody. Combining SAA1 with the PLA2R antibody, the area under the ROC curve was 0.956, which was higher than that of SAA1 or the PLA2R antibody alone. Conclusions: Serum SAA1 may be a candidate PMN biomarker that can be used to discriminate CNI NR cases from remission patients. The combination of SAA1 and the PLA2R antibody increases the accuracy of diagnosis.

Keywords:
Calcineurin inhibitors, Primary membranous nephropathy, Predictor, Proteomics, Serum amyloid A1 protein
1.
Xu X, Wang G, Chen N, Lu T, Nie S, Xu G, Zhang P, Luo Y, Wang Y, Wang X, Schwartz J, Geng J, Hou FF: Long-term exposure to air pollution and increased risk of membranous nephropathy in China. J Am Soc Nephrol 2016; 27: 3739–3746.
2.
Beck LH Jr, Salant DJ: Membranous nephropathy: from models to man. J Clin Invest 2014; 124: 2307–2314.
3.
Radhakrishnan J, Cattran DC: The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines – application to the individual patient. Kidney Int 2012; 82: 840–856.
4.
Xu J, Zhang W, Xu Y, Shen P, Ren H, Wang W, Li X, Pan X, Chen N: Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial. Contrib Nephrol 2013; 181: 152–162.
5.
Kalliakmani P, Koutroulia E, Sotsiou F, Vlachojannis JG, Goumenos DS: Benefit and cost from the long-term use of cyclosporine-A in idiopathic membranous nephropathy. Nephrology (Carlton) 2010; 15: 762–767.
6.
Shin DH, Lee MJ, Oh HJ, Koo HM, Doh FM, Kim HR, Han JH, Park JT, Han SH, Choi KH, Yoo TH, Kang SW: Stepwise treatment using corticosteroids alone and in combination with cyclosporine in korean patients with idiopathic membranous nephropathy. Yonsei Med J 2013; 54: 973–982.
7.
Hoxha E, Thiele I, Zahner G, Panzer U, Harendza S, Stahl RA: Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. J Am Soc Nephrol 2014; 25: 1357–1366.
8.
Tao J, Zhang W, Wen Y, Sun Y, Chen L, Li H, Li M, Li X, Lafayette RA, Li X: Endoplasmic reticulum stress predicts clinical response to cyclosporine treatment in primary membranous nephropathy. Am J Nephrol 2016; 43: 348–356.
9.
Altomare A, Fasoli E, Colzani M, Paredes Parra XM, Ferrari M, Cilurzo F, Rumio C, Cannizzaro L, Carini M, Righetti PG, Aldini G: An in depth proteomic analysis based on ProteoMiner, affinity chromatography and nano-HPLC-MS/MS to explain the potential health benefits of bovine colostrum. J Pharm Biomed Anal 2016; 121: 297–306.
10.
Byrne JC, Downes MR, O’Donoghue N, O’Keane C, O’Neill A, Fan Y, Fitzpatrick JM, Dunn M, Watson RW: 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009; 8: 942–957.
11.
Pourcine F, Dahan K, Mihout F, Cachanado M, Brocheriou I, Debiec H, Ronco P: Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years. PLoS One 2017; 12:e0173201.
12.
Uhlar CM, Burgess CJ, Sharp PM, Whitehead AS: Evolution of the serum amyloid A (SAA) protein superfamily. Genomics 1994; 19: 228–235.
13.
Sung HJ, Ahn JM, Yoon YH, Rhim TY, Park CS, Park JY, Lee SY, Kim JW, Cho JY: Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J Proteome Res 2011; 10: 1383–1395.
14.
Glojnaric I, Casl MT, Simic D, Lukac J: Serum amyloid A protein (SAA) in colorectal carcinoma. Clin Chem Lab Med 2001; 39: 129–133.
15.
Rho YH, Chung CP, Oeser A, Solus J, Asanuma Y, Sokka T, Pincus T, Raggi P, Gebretsadik T, Shintani A, Stein CM: Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009; 61: 1580–1585.
16.
Fyfe AI, Rothenberg LS, DeBeer FC, Cantor RM, Rotter JI, Lusis AJ: Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation 1997; 96: 2914–2919.
17.
Shen C, Sun XG, Liu N, Mu Y, Hong CC, Wei W, Zheng F: Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis. Mol Med Rep 2015; 11: 1528–1534.
18.
Cunnane G, Grehan S, Geoghegan S, McCormack C, Shields D, Whitehead AS, Bresnihan B, Fitzgerald O: Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000; 27: 58–63.
19.
Debiec H, Guigonis V, Mougenot B, Decobert F, Haymann JP, Bensman A, Deschenes G, Ronco PM: Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346: 2053–2060.
20.
Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22: 1543–1550.
21.
Tomas NM, Beck LH Jr, Meyer-Schwesinger C, Seitz-Polski B, Ma H, Zahner G, Dolla G, Hoxha E, Helmchen U, Dabert-Gay AS, Debayle D, Merchant M, Klein J, Salant DJ, Stahl RAK, Lambeau G: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371: 2277–2287.
22.
Wang J, Cui Z, Lu J, Probst C, Zhang YM, Wang X, Qu Z, Wang F, Meng LQ, Cheng XY, Liu G, Debiec H, Ronco P, Zhao MH: Circulating antibodies against thrombospondin type-I domain-containing 7A in Chinese patients with idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2017; 12: 1642–1651.
23.
Gabay C, Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340: 448–454.
24.
Urieli-Shoval S, Cohen P, Eisenberg S, Matzner Y: Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J Histochem Cytochem 1998; 46: 1377–1384.
25.
Benditt EP, Eriksen N: Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc Natl Acad Sci U S A 1977; 74: 4025–4028.
26.
Pertovaara M, Jylhava J, Uusitalo H, Pukander J, Helin H, Hurme M: Serum amyloid A and C-reactive protein concentrations are differently associated with markers of autoimmunity in patients with primary Sjogren’s syndrome. J Rheumatol 2009; 36: 2487–2490.
27.
Penny MJ, Boyd RA, Hall BM: Permanent CD8(+) T cell depletion prevents proteinuria in active Heymann nephritis. J Exp Med 1998; 188: 1775–1784.
28.
Penny MJ, Boyd RA, Hall BM: Role of T cells in the mediation of Heymann nephritis. ii. Identification of Th1 and cytotoxic cells in glomeruli. Kidney Int 1997; 51: 1059–1068.
29.
De Santo C, Arscott R, Booth S, Karydis I, Jones M, Asher R, Salio M, Middleton M, Cerundolo V: Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nat Immunol 2010; 11: 1039–1046.
30.
Skornicka EL, Kiyatkina N, Weber MC, Tykocinski ML, Koo PH: Pregnancy zone protein is a carrier and modulator of placental protein-14 in T-cell growth and cytokine production. Cell Immunol 2004; 232: 144–156.
31.
Silliman CC, Dzieciatkowska M, Moore EE, Kelher MR, Banerjee A, Liang X, Land KJ, Hansen KC: Proteomic analyses of human plasma: venus versus mars. Transfusion 2012; 52: 417–424.
32.
Li D, Dong H, Li S, Munir M, Chen J, Luo Y, Sun Y, Liu L, Qiu HJ: Hemoglobin subunit beta interacts with the capsid protein and antagonizes the growth of classical swine fever virus. J Virol 2013; 87: 5707–5717.
33.
Carneiro LG, Nouh H, Salih E: Quantitative gingival crevicular fluid proteome in health and periodontal disease using stable isotope chemistries and mass spectrometry. J Clin Periodontol 2014; 41: 733–747.
34.
Xiao H, Zhang Y, Kim Y, Kim S, Kim JJ, Kim KM, Yoshizawa J, Fan LY, Cao CX, Wong DT: Differential proteomic analysis of human saliva using tandem mass tags quantification for gastric cancer detection. Sci Rep 2016; 6: 22165.
35.
Littlejohns B, Heesom K, Angelini GD, Suleiman MS: The effect of disease on human cardiac protein expression profiles in paired samples from right and left ventricles. Clin Proteomics 2014; 11: 34.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.